Premium
Long‐term results of corpus cavernosum autoinjection therapy for chronic erectile dysfunction
Author(s) -
Gall H.,
Sparwasser C.,
Bähren W.,
Scherb W.,
Irion R.
Publication year - 2009
Publication title -
andrologia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.633
H-Index - 59
eISSN - 1439-0272
pISSN - 0303-4569
DOI - 10.1111/j.1439-0272.1992.tb02654.x
Subject(s) - papaverine , erectile dysfunction , medicine , phentolamine , urology , etiology , penis , surgery , anesthesia , propranolol
Summary. Between May 1985 and March 1992, 172 patients suffering from chronic erectile dysfunction (21–70 years old) underwent constant corpus cavernosum autoinjection therapy (CAT) with a standardized papaverine‐phentolamine mixture (16385 injections). Thereafter 41 patients continued CAT with the single agent papaverine (1257 injections). On the basis of both these 17642 protocol auto‐injections, and over 6 years of experience with intracavernosal autoinjection therapy we conclude that, especially with the papaverine‐phentolamine mixture, CAT constitutes an effective therapy (full rigidity in 95.8%) with tolerable side‐effects for chronic erectile dysfunction when preceded by careful patient selection and thorough multi‐disciplinary evaluation. This is especially so in the case of arterial and/or neurogenic aetiology of the erectile dysfunction. In addition, the contraindications must be strictly observed, the treatment and technique fully explained, and a regular follow‐up instituted. CAT is generally well accepted by the patients and their partners (98.8% /97.6%) and has distinct positive effects on self‐esteem (77.8%), performance anxiety (84.4%), and partnership (79.5%). The most serious side‐effect was prolonged erection (25 out of 17642 injections). In 6 patients reversible fibrotic changes near the tunica albuginea were observed.